Balancing risk versus benefit in the treatment of Waldenström's macroglobulinemia patients with nucleoside analogue-based therapy

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 71-73

  Leleu, Xavier ^a,b   Tamburini, Jérome ^c   Roccaro, Aldo ^a   Morel, Pierre ^d   Soumerai, Jacob ^a   Lévy, Vincent ^c   Wemeau, Mathieu ^b   Balkaran, Sandy ^b   Poulain, Stephanie ^b   Hunter, Zachary ^a   Ghobrial, Irene ^a   Treon, Steven ^a   Leblond, Veronique ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Schaffner Hospital   (France)

Author keywords

High grade NHL transformation; Therapy related myelodysplastic syndrome acute myeloid leukemia; Waldenstr m

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUDARABINE; NUCLEOSIDE ANALOG; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; NUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; EUROPE; HODGKIN DISEASE; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNITED STATES; WALDENSTROEM MACROGLOBULINEMIA; DISEASE COURSE; PATHOLOGY;

DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; NUCLEOSIDES; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649522702     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.018     Document Type: Article

References (18)

1. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107:3442-6.
2. Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood 2007; 5096-103.
3. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24:2343-51.
4. Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005; 29:389-95.
5. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004; 103:1222-8.
6. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878-84.
7. Bowcock SJ, Rassam SM, Lim Z, et al. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br J Haematol 2006; 134:242-3.
8. Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91:1546-50.
9. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 1998;16:2060-4.
10. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98:2640-4.
11. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia 2005; 19:1831-4.
12. Hamada T, Ishizuka H, Asai Y, et al. A case of anaplastic large cell (Ki-1) lymphoma of B-cell phenotype, occurring in Waldenstrom's macroglobulinemia. Pathol Int 1999; 49:913-7.
13. Ling S, Joshua DE, Gibson J, et al. Transformation and progression of Waldenstrom's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation? Am J Hematol 2006; 81:110-4.
14. Lin P, Mansoor A, Bueso-Ramos C, et al. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003; 120:246-53.
15. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-8.
16. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575-82.
17. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108:737-42.
18. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158-64.